Company intelligence
Imbria Pharmaceuticals
Unlocking the power of cardiac energy metabolism
About Imbria Pharmaceuticals
Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.
Verified activity
Signals from Imbria Pharmaceuticals
3 published signals
Research & Knowledge
Imbria Pharmaceuticals is conducting the FORTITUDE-HCM Phase 2b clinical trial evaluating ninerafaxstat in adults with symptomatic non-obstructive hypertrophic cardiomyopathy.
Reported by Imbria Pharmaceuticals
Research & Knowledge
Imbria Pharmaceuticals shared updates on its ongoing Phase 2b FORTITUDE-HCM trial in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) at the ESC Congress.
Reported by Imbria Pharmaceuticals
Research & Knowledge
Imbria Pharmaceuticals published clinical trial data showing that relaxin may become a foundational medical therapy for heart failure.
Reported by James Januzzi